Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OptiScan Biomedical Corporation

http://optiscancorp.com/

Latest From OptiScan Biomedical Corporation

Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf

AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.

Deal Watch Business Strategies

Finance Watch: IPOs At A Standstill As US Biotech Stock Valuations Plummet

There have been no biopharma initial public offerings in the US since 12 January while the industry’s valuations have plummeted by double digits since the start of 2022. Nevertheless, venture capital investment continues at a fast pace and there have been some follow-on public offerings.

Financing Business Strategies

Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022

Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.

China Financing

2021 Marked New Era Of Domestic Collaboration in China

Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.

China Scrip Perspectives
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Glucose Testing
UsernamePublicRestriction

Register